Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland
Tóm tắt
Salivary ductal carcinoma (SDC) of parotid gland is a rare and aggressive entity; accounting for 1–3 % of all malignant salivary gland tumors, 0.2 % of epithelial salivary gland neoplasms, 0.5 % of salivary gland carcinomas, and 1.1 % of parotid gland carcinomas. Here in we aimed to evaluate the clinico-pathological features and treatment outcomes of parotid gland SDC in Saudi population. Among 38 patients with parotid malignancies, who were treated in two major tertiary care referral cancer centers between December 2007 and December 2014, seven cases (18.4 %) were found to have SDC, which were investigated for clinicopathological features, locoregional recurrences (LRRs), distant metastasis (DM) and survival rates. Mean age of cohort was 62.3 years (range: 41–83) and female predominant (71.4 %). All patients underwent total parotidectomy and ipsilateral neck dissection. Mean tumor size was 3.4 cm (range: 2.1–5.3); perineural invasion (85.8 %); lymph node involvement (42.9 %); and HER-2 neu overexpression (28.6 %). Postoperative radiation therapy (PORT) was given to six patients (dose: 50–66 Gy). Median follow-up was 20.2 months (range: 11–48). LRRs were seen in five (71.4 %) patients (base of skull, 3 patients; cervical nodes, one patient; parotid bed, one patient). LRRs were salvaged with resection (two patients) and re-irradiation (one patient with base of skull). DM in lungs was seen in three patients (42.8 %); one treated with carboplatin/paclitaxel based chemotherapy. The 4-year disease free and overall survival rates were 16.7 % and 40 % respectively. SDC of parotid gland is a rare and aggressive entity, and most of LRRs were seen in the base of skull, which warrants inclusion of base of skull in clinical target volume in PORT planning. Role of anti HER-2 targeted therapy in SDC with HER-2 neu overexpression needs further investigations.
Từ khóa
Tài liệu tham khảo
Pont E, Pla A, Cruz Mojarrieta J, Ferrandis E, Brotons S, Vendrell JB. Salivary duct carcinoma: diagnostic clues, histology and treatment. Acta Otorrinolaringol Esp. 2013;64:150–3.
Xie S, Yang H, Bredell M, Shen S, Yang H, Jin L, Zhang S. Salivary duct carcinoma of the parotid gland: A case report and review of the literature. Oncol Lett. 2015;9:371–4.
Huang X, Hao J, Chen S, Deng R. Salivary duct carcinoma: A clinopathological report of 11 cases. Oncol Lett. 2015;10:337–41.
Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005;103:2526–33.
Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007;29:907–12.
Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U, Kim S. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma. JAMA Otolaryngol Head Neck Surg. 2016. doi:10.1001/jamaoto.2015.3930.
Johnston ML, Huang SH, Waldron JN, Atenafu EG, Chan K, Cummings BJ, Gilbert RW, Goldstein D, Gullane PJ, Irish JC, Perez-Ordonez B, Weinreb I, Bayley A, Cho J, Dawson LA, Hope A, Ringash J, Witterick IJ, O'Sullivan B, Kim J. Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. Head Neck. 2015. doi:10.1002/hed.24107.
Roh JL, Lee JI, Choi SH, Nam SY, Kim SO, Cho KJ, Kim SB, Kim SY. Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: high rate of systemic failure warrants targeted therapy. Oral Oncol. 2014;50:e64–6.
Jayaprakash V, Merzianu M, Warren GW, Arshad H, Hicks Jr WL, Rigual NR, Sullivan MA, Seshadri M, Marshall JR, Cohan DM, Zhao Y, Singh AK. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck. 2014;36:694–70.
Kim TH, Kim MS, Choi SH, Suh YG, Koh YW, Kim SH, Choi EC, Keum KC. Postoperative radiotherapy in salivary ductal carcinoma: a single institution experience. Radiat Oncol J. 2014;32:125–31.
Shi S, Fang Q, Liu F, Zhong M, Sun C. Prognostic factors and survival rates for parotid duct carcinoma patients. J Craniomaxillofac Surg. 2014;42:1929–31.
Kim JY, Lee S, Cho KJ, Kim SY, Nam SY, Choi SH, Roh JL, Choi EK, Kim JH, Song SY, Shin HS, Chang SK, Ahn SD. Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands. Br J Radiol. 2012;85:e947–52.
Brandwein-Gensler M, Hille J, Wang BY, Urken M, Gordon R, Wang LJ, Simpson JR, Simpson RH, Gnepp DR. Low-grade salivary duct carcinoma: description of 16 cases. Am J Surg Pathol. 2004;28:1040–44.
Luna MA, Batsakis JG, Ordonez NG, Mackay B, Tortoledo ME. Salivary gland adenocarcinomas: a clinicopathologic analysis of three distinctive types. Semin Diagn Pathol. 1987;4:117–35.
Colmenero Ruiz C, Patron Romero M, Martin PM. Salivary duct carcinoma: a report of nine cases. J Oral Maxillofac Surg. 1993;51:641–6.
Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer. 1993;72:1503–12.
Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck. 1997;19:126–33.
Hosal AS, Fan C, Barnes L, Myers EN. Salivary duct carcinoma. Otolaryngol Head Neck Surg. 2003;129:720–5.
Ko YH, Roh JH, Son YI, Chung MK, Jang JY, Byun H, Baek CH, Jeong HS. Expression of mitotic checkpoint proteins BUB1B and MAD2L1 in salivary duct carcinomas. J Oral Pathol Med. 2010;39:349–55.
Afzelius LE, Cameron WR, Svensson C. Salivary duct carcinoma-a clinicopathologic study of 12 cases. Head Neck Surg. 1987;9:151–6.
Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77:223–30.
Shinoto M, Shioyama Y, Nakamura K, Nakashima T, Kunitake N, Higaki Y, Sasaki T, Ohga S, Yoshitake T, Ohnishi K, Asai K, Hirata H, Honda H. Postoperative radiotherapy in patients with salivary duct carcinoma: clinical outcomes and prognostic factors. J Radiat Res. 2013;54:925–30.
Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013;18:294–300.
McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002;62:209–43.
Masubuchi T, Tada Y, Maruya S, Osamura Y, Kamata SE, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, Nagao T. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol. 2015;20:35–44.
Simpson RH, Skalova A, Di Palma S, Leivo I. Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch. 2014;465:371–84.
Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys. 1995;32:619–26.
Jensen AD, Poulakis M, Nikoghosyan AV, Chaudhri N, Uhl M, Munter MW, Herfarth KK, Debus J. Re-irradiation of adenoid cystic carcinoma: analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy. Radiother Oncol. 2015;114:182-8.